1. Scrip
  2. >>Archive

Amarin granted nod to market fish oil pill

 
• By Donna Young

After causing a rumpus last week when a staging website went live unexpectedly before Amarin got the official nod from the US FDA for an experimental fish oil pill, the firm revealed after the bell on 26 July that it had indeed been granted the OK to market the drug in the US under the brand name Vascepa.

After causing a rumpus last week when a staging website went live unexpectedly before Amarin got the official nod from the US FDA for an experimental fish oil pill, the firm revealed after the bell on 26 July that it had indeed been granted the OK to market the drug in the US under the brand name Vascepa.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

 
• By Mandy Jackson

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.

Novartis Gains Further Renal Territory With Regulus Acquisition

 
• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.